Jeff Gerth was a senior reporter at ProPublica. Previously, he worked as an investigative reporter at The New York Times from 1976 through 2005. His work has twice been honored with the Pulitzer Prize. He also won a George Polk Award. His often-prescient coverage has run the gamut from Al Qaeda to Enron, from Whitewater to Chinese technology transfers. During 2004 he was a visiting professor at Princeton University, where he taught an undergraduate seminar on investigative reporting. Gerth is also the co-author (with Don Van Natta Jr.), of Her Way: The Hopes and Ambitions of Hillary Rodham Clinton, published in 2007.
Most Americans know that overdosing can be dangerous but many wrongly think it’s safe to mix drugs containing acetaminophen, a nationwide poll found.
We explore the data behind figures showing how many people die from overdosing on acetaminophen, the active ingredient in Tylenol.
A jury awarded $5 million to a patient and his wife after it found GE Healthcare didn’t adequately warn patients and doctors about the risk of its imaging dye, Omniscan. It was the first case involving the dye to go to trial.
A groundbreaking trial over GE Healthcare's imaging dye Omniscan reveals new evidence that a rare but terrible side effect might have been downplayed. GE says the evidence is being twisted and that it acted ethically.
In a major win for the IRS, a federal tax court judge ruled that BNY Mellon improperly claimed foreign tax credits. The bank announced it would take an $850 million charge but that it would also appeal.
Gunvor, co-owned by a Russian tycoon, bought into a Montana coal mine and doubled production. But falling coal prices and a lawsuit have created obstacles.
Following years of neglect and a ProPublica story last week, regulators are about to tell phone companies to comply with a rule that they charge bargain rates to schools.
To help avert a digital divide between rich and poor students, Congress required phone companies to offer bargain rates to schools. But as schools struggle for funding, evidence shows that this low-price requirement has been widely neglected.
A trial starting Monday in tax court will decide whether a complex financial deal developed by Barclays allowed the Bank of New York to claim foreign tax credits for “phantom” expenses booked in the U.K.
The 'check-the-box' rule, meant to cut red tape for companies, has inadvertently allowed them to avoid billions of dollars in taxes each year, and the government keeps balking at closing the loophole.
The Internal Revenue Service says STARS transactions marketed by the British bank Barclays generated undeserved foreign tax credits for six U.S. banks, which say the complex deals were legitimate low-cost loans.
STARS deals weren't the only ones that took advantage of cross-border differences in law to reap hundreds of millions of dollars in tax breaks.
Did GE pay U.S. income taxes in 2010? The company known for minimizing its tax bill made a muddled situation worse responding to a New York Times report suggesting it might get a refund. GE now says it has a small tax liability for 2010.
GE is in a class by itself when it comes to paring its tax rate well below the top U.S. corporate rate of 35 percent – sometimes into the single digits – using an array of strategies that include hiring top tax experts from IRS and Treasury.
The last-minute deal keeps confidential company documents that could shed new light on claims that GE’s drug, used to enhance MRIs, caused a crippling disease in patients with bad kidneys and that the company hid its risks
An elderly Minnesota woman and her husband claim General Electric hid the risks of the company’s MRI drug Omniscan, causing her to contract a crippling disease.
General Electric Co. borrowed $16 billion through a Federal Reserve Board rescue program in the fall of 2008, even as the blue-ribbon company enjoyed the highest credit rating available at the time.
In a setback for GE Healthcare, the U.S. Food and Drug Administration has announced new labeling requirements that ban use of the contrast agent Omniscan and two other drugs in patients with severe kidney disease, who could be at risk of a crippling and fatal disease.
Danish drug regulators concluded in a ruling last month that GE's health care unit failed to promptly and completely inform regulators about a patient who died after experiencing adverse effects from the company's MRI drug Omniscan. Though that's a violation of Danish law, the regulators said the statute of limitations had expired and they wold pursue no further action.
A ruling by a Cleveland judge will allow most of the plaintiffs' expert witnesses to testify about the MRI drug Omniscan. The ruling covers hundreds of lawsuits against General Electric’s health care unit.